Skeletal muscle metabolism in the pathology and treatment of type 1 diabetes

Current Pharmaceutical Design

Volumn 16, Issue 8, 2010, Pages 1002-1020

  Mann, C J ^a,b   Ayuso, E ^a,b   Anguela, X M ^a,b   Bosch, F ^a,b  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

Diabetes; Exercise; Gene therapy; Glucose; Insulin; Metabolism; Skeletal muscle

Indexed keywords

FURIN; GLUCOKINASE; GLUCOSE TRANSPORTER 4; INSULIN; INSULIN DERIVATIVE; INSULIN RECEPTOR; VASCULOTROPIN;

EXERCISE; GENE THERAPY; GENETIC ENGINEERING; GLUCOSE HOMEOSTASIS; GLUCOSE METABOLISM; GLUCOSE TRANSPORT; HUMAN; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RELEASE; INSULIN SYNTHESIS; LIPID METABOLISM; MUSCLE METABOLISM; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; PROMOTER REGION; QUALITY OF LIFE; REVIEW; SIGNAL TRANSDUCTION; SKELETAL MUSCLE; VIRAL GENE THERAPY;

ANIMALS; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 1; EXERCISE; GENE THERAPY; GENE TRANSFER TECHNIQUES; HUMANS; INSULIN; MODELS, BIOLOGICAL; MUSCLE, SKELETAL;

EID: 77950270414     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161210790883435     Document Type: Review

References (255)

1. Matsakas A, Patel K. Skeletal muscle fibre plasticity in response to selected environmental and physiological stimuli. Histol Histopathol 2009; 24: 611-629
2. Fluck M, Hoppeler H. Molecular basis of skeletal muscle plasticity - from gene to form and function. Rev Physiol Biochem Pharmacol 2003; 146: 159-216.
3. Argiles JM, Lopez-Soriano J, Almendro V, Busquets S, Lopez-Soriano FJ. Cross-talk between skeletal muscle and adipose tissue: a link with obesity? Med Res Rev 2005; 25: 49-65.
4. Pedersen BK, Febbraio MA. Muscle as an endocrine organ: focus on muscle-derived interleukin-6. Physiol Rev 2008; 88: 1379-1406
5. Nielsen S, Pedersen BK. Skeletal muscle as an immunogenic organ. Curr Opin Pharmacol 2008; 8: 346-351
6. Wiendl H, Hohlfeld R, Kieseier BC. Immunobiology of muscle: advances in understanding an immunological microenvironment. Trends Immunol 2005; 26: 373-380
7. DeFronzo RA, Jacot E, Jequier E, Maeder E, Wahren J, Felber JP. The effect of insulin on the disposal of intravenous glucose. Results from indirect calorimetry and hepatic and femoral venous catheterization. Diabetes 1981; 30: 1000-1007
8. Phielix E, Mensink M. Type 2 diabetes mellitus and skeletal muscle metabolic function. Physiol Behav 2008; 94: 252-258
9. Storgaard H, Jensen CB, Bjornholm M, Song XM, Madsbad S, Zierath JR, et al. Dissociation between fat-induced in vivo insulin resistance and proximal insulin signaling in skeletal muscle in men at risk for type 2 diabetes. J Clin Endocrinol Metab 2004; 89: 1301-1311
10. Brons C, Vaag A. Skeletal muscle lipotoxicity in insulin resistance and type 2 diabetes. J Physiol 2009; 587: 3977-3978
11. rd ed. Chichester: John Wiley and Sons, Ltd. 2004; vol.1, pp. 15-31.
12. Tisch R, McDevitt H. Insulin-dependent diabetes mellitus. Cell 1996; 85: 291-297
13. Miles HL, Acerini CL. Insulin analog preparations and their use in children and adolescents with type 1 diabetes mellitus. Paediatr Drugs 2008; 10: 163-176
14. Hartman I. Insulin analogs: impact on treatment success, satisfaction, quality of life, and adherence. Clin Med Res 2008; 6: 54-67.
15. Pouwer F, Hermanns N. Insulin therapy and quality of life. A review. Diabetes Metab Res Rev 2009; 25 (Suppl 1): S4-10.
16. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature 2001; 414: 813-820
17. Brownlee M. The pathobiology of diabetic complications: a unifying mechanism. Diabetes 2005; 54: 1615-1625
18. White SA, Shaw JA, Sutherland DE. Pancreas transplantation. Lancet 2009; 373: 1808-1817
19. Shapiro AM, Lakey JR, Ryan EA, Korbutt GS, Toth E, Warnock GL, et al. Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen. N Engl J Med 2000; 343: 230-238
20. Kobayashi N. Cell therapy for diabetes mellitus. Cell Transplant 2006; 15: 849-854
21. Guo T, Hebrok M. Stem cells to pancreatic beta-cells: new sources for diabetes cell therapy. Endocr Rev 2009; 30: 214-227
22. Agudo J, Ayuso E, Jimenez V, Salavert A, Casellas A, Tafuro S, et al. IGF-I mediates regeneration of endocrine pancreas by increasing beta cell replication through cell cycle protein modulation in mice. Diabetologia 2008; 51: 1862-1872
23. Jun HS. Regeneration of pancreatic beta cells. Front Biosci 2008; 13: 6170-6182
24. George M, Ayuso E, Casellas A, Costa C, Devedjian JC, Bosch F. Beta cell expression of IGF-I leads to recovery from type 1 diabetes. J Clin Invest 2002; 109: 1153-1163
25. Evans-Molina C, Vestermark GL, Mirmira RG. Development of insulin-producing cells from primitive biologic precursors. Curr Opin Organ Transplant 2009; 14: 56-63.
26. Hampe CS. Engineered antibodies for type 1 diabetes. Curr Opin Investig Drugs 2009; 10: 336-345
27. Jones D. Retuning the immune system: the future of type 1 diabetes therapy? Nat Rev Drug Discov 2009; 8: 600-601
28. Cernea S, Pozzilli P. New potential treatments for protection of pancreatic B-cell function in Type 1 diabetes. Diabet Med 2008; 25: 1259-1267
29. Wang Z, Zhu T, Rehman KK, Bertera S, Zhang J, Chen C, et al. Widespread and stable pancreatic gene transfer by adeno-associated virus vectors via different routes. Diabetes 2006; 55: 875-884
30. Ayuso E, Chillon M, Agudo J, Haurigot V, Bosch A, Carretero A, et al. In vivo gene transfer to pancreatic β cells by systemic delivery of adenoviral vectors. Hum Gene Ther 2004; 15: 805-812
31. Ayuso E, Chillon M, Garcia F, Agudo J, Andaluz A, Carretero A, et al. In vivo gene transfer to healthy and diabetic canine pancreas. Mol Ther 2006; 13: 747-755
32. Lu QL, Bou-Gharios G, Partridge TA. Non-viral gene delivery in skeletal muscle: a protein factory. Gene Ther 2003; 10: 131-142
33. Pette D, Staron RS. Myosin isoforms, muscle fiber types, and transitions. Microsc Res Technol 2000; 50: 500-509
34. Needham DM. Red and white muscle. Physiol Rev 1926; 6: 1-27.
35. Scott W, Stevens J, Binder-Macleod SA. Human skeletal muscle fiber type classifications. Phys Ther 2001; 81: 1810-1816
36. Sciote JJ, Horton MJ, Rowlerson AM, Link J. Specialized cranial muscles: how different are they from limb and abdominal muscles? Cells Tissues Organs 2003; 174: 73-86.
37. Fisher KJ, Jooss K, Alston J, Yang Y, Haecker SE, High K, et al. Recombinant adeno-associated virus for muscle directed gene therapy. Nat Med 1997; 3: 306-312
38. Snyder RO, Spratt SK, Lagarde C, Bohl D, Kaspar B, Sloan B, et al. Efficient and stable adeno-associated virus-mediated transduction in the skeletal muscle of adult immunocompetent mice. Hum Gene Ther 1997; 8: 1891-1900
39. Pruchnic R, Cao B, Peterson ZQ, Xiao X, Li J, Samulski RJ, et al. The use of adeno-associated virus to circumvent the maturation-dependent viral transduction of muscle fibers. Hum Gene Ther 2000; 11: 521-536
40. Louboutin JP, Wang L, Wilson JM. Gene transfer into skeletal muscle using novel AAV serotypes. J Gene Med 2005; 7: 442-451
41. Taylor R, Agius L. The biochemistry of diabetes. Biochem J 1988; 250: 625-640
42. Stipanuk MH. In: MH Stipanuk, Ed. Biochemical, physiological and molecular aspects of human nutrition. St. Louis, Saunders Elsevier 2006; pp. 566-589
43. rd ed. USA: McGraw-Hill 2004; vol.1, pp. 535-564
44. DeFronzo RA, Ferrannini E. Influence of plasma glucose and insulin concentration on plasma glucose clearance in man. Diabetes 1982; 31: 683-688
45. DeFronzo RA, Gunnarsson R, Bjorkman O, Olsson M, Wahren J. Effects of insulin on peripheral and splanchnic glucose metabolism in noninsulin-dependent (type II) diabetes mellitus. J Clin Invest 1985; 76: 149-155
46. Taniguchi CM, Emanuelli B, Kahn CR. Critical nodes in signalling pathways: insights into insulin action. Nat Rev Mol Cell Biol 2006; 7: 85-96.
47. Pessin JE, Saltiel AR. Signaling pathways in insulin action: molecular targets of insulin resistance. J Clin Invest 2000; 106: 165-169
48. Saltiel AR, Kahn CR. Insulin signalling and the regulation of glucose and lipid metabolism. Nature 2001; 414: 799-806.
49. Baumann CA, Saltiel AR. Spatial compartmentalization of signal transduction in insulin action. Bioessays 2001; 23: 215-222
50. Avruch J. Insulin signal transduction through protein kinase cascades. Mol Cell Biochem 1998; 182: 31-48.
51. Gross DN, van den Heuvel AP, Birnbaum MJ. The role of FoxO in the regulation of metabolism. Oncogene 2008; 27: 2320-2336
52. Araki E, Lipes MA, Patti ME, Bruning JC, Haag B, 3rd, Johnson RS, et al. Alternative pathway of insulin signalling in mice with targeted disruption of the IRS-1 gene. Nature 1994; 372: 186-190
53. Huang C, Thirone AC, Huang X, Klip A. Differential contribution of insulin receptor substrates 1 versus 2 to insulin signaling and glucose uptake in l6 myotubes. J Biol Chem 2005; 280: 19426-19435
54. Antonetti DA, Algenstaedt P, Kahn CR. Insulin receptor substrate 1 binds two novel splice variants of the regulatory subunit of phosphatidylinositol 3-kinase in muscle and brain. Mol Cell Biol 1996; 16: 2195-2203
55. Zorzano A, Palacin M, Guma A. Mechanisms regulating GLUT4 glucose transporter expression and glucose transport in skeletal muscle. Acta Physiol Scand 2005; 183: 43-58.
56. Fueger PT. Glucose phosphorylation as a barrier to muscle glucose uptake. Clin Exp Pharmacol Physiol 2005; 32: 314-318
57. Henriksen EJ, Bourey RE, Rodnick KJ, Koranyi L, Permutt MA, Holloszy JO. Glucose transporter protein content and glucose transport capacity in rat skeletal muscles. Am J Physiol 1990; 259: E593-8.
58. Song XM, Ryder JW, Kawano Y, Chibalin AV, Krook A, Zierath JR. Muscle fiber type specificity in insulin signal transduction. Am J Physiol 1999; 277: R1690-6.
59. Daugaard JR, Nielsen JN, Kristiansen S, Andersen JL, Hargreaves M, Richter EA. Fiber type-specific expression of GLUT4 in human skeletal muscle: influence of exercise training. Diabetes 2000; 49: 1092-1095
60. Hegarty BD, Turner N, Cooney GJ, Kraegen EW. Insulin resistance and fuel homeostasis: the role of AMP-activated protein kinase. Acta Physiol (Oxford) 2009; 196: 129-145
61. Zhao C, Wang Z, Robertson MW, Davies JD. Cachexia in the non-obese diabetic mouse is associated with CD4+ T-cell lymphopenia. Immunology 2008; 125: 48-58.
62. Glass DJ. Signalling pathways that mediate skeletal muscle hypertrophy and atrophy. Nat Cell Biol 2003; 5: 87-90.
63. Bolster DR, Jefferson LS, Kimball SR. Regulation of protein synthesis associated with skeletal muscle hypertrophy by insulin-, amino acid- and exercise-induced signalling. Proc Nutr Soc 2004; 63: 351-356
64. Vodenik B, Rovira J, Campistol JM. Mammalian target of rapamycin and diabetes: what does the current evidence tell us? Transplant Proc 2009; 41: S31-8.
65. Price SR, Bailey JL, Wang X, Jurkovitz C, England BK, Ding X, et al. Muscle wasting in insulinopenic rats results from activation of the ATP-dependent, ubiquitin-proteasome proteolytic pathway by a mechanism including gene transcription. J Clin Invest 1996; 98: 1703-1708
66. Mitch WE, Bailey JL, Wang X, Jurkovitz C, Newby D, Price SR. Evaluation of signals activating ubiquitin-proteasome proteolysis in a model of muscle wasting. Am J Physiol 1999; 276: C1132-8.
67. Bassel-Duby R, Olson EN. Signaling pathways in skeletal muscle remodeling. Annu Rev Biochem 2006; 75: 19-37.
68. Miyazaki M, Esser KA. Cellular mechanisms regulating protein synthesis and skeletal muscle hypertrophy in animals. J Appl Physiol 2009; 106: 1367-1373
69. rd ed. Chichester: John Wiley and Sons, Ltd. 2004; vol.1, pp. 951-979
70. Pette D, Staron RS. Transitions of muscle fiber phenotypic profiles. Histochem Cell Biol 2001; 115: 359-372
71. rd ed. Chichester: John Wiley and Sons, Ltd. 2004; vol.1, pp. 771-794
72. Jorgensen SB, Richter EA, Wojtaszewski JF. Role of AMPK in skeletal muscle metabolic regulation and adaptation in relation to exercise. J Physiol 2006; 574: 17-31.
73. Kiens B. Skeletal muscle lipid metabolism in exercise and insulin resistance. Physiol Rev 2006; 86: 205-243
74. Hawley JA, Lessard SJ. Exercise training-induced improvements in insulin action. Acta Physiol (Oxf) 2008; 192: 127-135
75. Wasserman DH, Mohr T, Kelly P, Lacy DB, Bracy D. Impact of insulin deficiency on glucose fluxes and muscle glucose metabolism during exercise. Diabetes 1992; 41: 1229-1238
76. Fujita S, Abe T, Drummond MJ, Cadenas JG, Dreyer HC, Sato Y, et al. Blood flow restriction during low-intensity resistance exercise increases S6K1 phosphorylation and muscle protein synthesis. J Appl Physiol 2007; 103: 903-910
77. Colberg SR. Physical activity, insulin action, and diabetes prevention and control. Curr Diabetes Rev 2007; 3: 176-184
78. Colberg SR, Grieco CR. Exercise in the treatment and prevention of diabetes. Curr Sports Med Rep 2009; 8: 169-175
79. Brooks GA, Mercier J. Balance of carbohydrate and lipid utilization during exercise: the "crossover" concept. J Appl Physiol 1994; 76: 2253-2261
80. Andersen P, Saltin B. Maximal perfusion of skeletal muscle in man. J Physiol 1985; 366: 233-249
81. Bloor CM. Angiogenesis during exercise and training. Angiogenesis 2005; 8: 263-271
82. Richardson RS, Wagner H, Mudaliar SR, Henry R, Noyszewski EA, Wagner PD. Human VEGF gene expression in skeletal muscle: effect of acute normoxic and hypoxic exercise. Am J Physiol 1999; 277: H2247-52.
83. Henriksen EJ. Improvement of insulin sensitivity by antagonism of the renin-angiotensin system. Am J Physiol Regul Integr Comp Physiol 2007; 293: R974-80.
84. Brown MD, Hudlicka O. Modulation of physiological angiogenesis in skeletal muscle by mechanical forces: involvement of VEGF and metalloproteinases. Angiogenesis 2003; 6: 1-14.
85. Baron AD, Brechtel G. Insulin differentially regulates systemic and skeletal muscle vascular resistance. Am J Physiol 1993; 265: E61-7.
86. Steinberg HO, Brechtel G, Johnson A, Fineberg N, Baron AD. Insulin-mediated skeletal muscle vasodilation is nitric oxide dependent. A novel action of insulin to increase nitric oxide release. J Clin Invest 1994; 94: 1172-1179
87. Vincent MA, Clerk LH, Lindner JR, Klibanov AL, Clark MG, Rattigan S, et al. Microvascular recruitment is an early insulin effect that regulates skeletal muscle glucose uptake in vivo. Diabetes 2004; 53: 1418-1423
88. Sarafidis PA, McFarlane SI, Bakris GL. Antihypertensive agents, insulin sensitivity, and new-onset diabetes. Curr Diab Rep 2007; 7: 191-199
89. Daugaard JR, Richter EA. Relationship between muscle fibre composition, glucose transporter protein 4 and exercise training: possible consequences in non-insulin-dependent diabetes mellitus. Acta Physiol Scand 2001; 171: 267-276
90. Stuart CA, Howell ME, Yin D. Overexpression of GLUT5 in diabetic muscle is reversed by pioglitazone. Diabetes Care 2007; 30: 925-931
91. Gaster M, Handberg A, Schurmann A, Joost HG, Beck-Nielsen H, Schroder HD. GLUT11, but not GLUT8 or GLUT12, is expressed in human skeletal muscle in a fibre type-specific pattern. Pflugers Arch 2004; 448: 105-113
92. Rose AJ, Richter EA. Skeletal muscle glucose uptake during exercise: how is it regulated? Physiology (Bethesda) 2005; 20: 260-270
93. Fueger PT, Hess HS, Posey KA, Bracy DP, Pencek RR, Charron MJ, et al. Control of exercise-stimulated muscle glucose uptake by GLUT4 is dependent on glucose phosphorylation capacity in the conscious mouse. J Biol Chem 2004; 279: 50956-50961
94. Fueger PT, Heikkinen S, Bracy DP, Malabanan CM, Pencek RR, Laakso M, et al. Hexokinase II partial knockout impairs exercis-estimulated glucose uptake in oxidative muscles of mice. Am J Physiol Endocrinol Metab 2003; 285: E958-63.
95. Katz A, Broberg S, Sahlin K, Wahren J. Leg glucose uptake during maximal dynamic exercise in humans. Am J Physiol 1986; 251: E65-70.
96. Kristiansen S, Hargreaves M, Richter EA. Exercise-induced increase in glucose transport, GLUT-4, and VAMP-2 in plasma membrane from human muscle. Am J Physiol 1996; 270: E197-201.
97. Derave W, Lund S, Holman GD, Wojtaszewski J, Pedersen O, Richter EA. Contraction-stimulated muscle glucose transport and GLUT-4 surface content are dependent on glycogen content. Am J Physiol 1999; 277: E1103-10.
98. Vogt C, Yki-Jarvinen H, Iozzo P, Pipek R, Pendergrass M, Koval J, et al. Effects of insulin on subcellular localization of hexokinase II in human skeletal muscle in vivo. J Clin Endocrinol Metab 1998; 83: 230-234
99. Wilson JE. Distinguishing the type I and type II isozymes of hexokinase: the need for a reexamination of past practice. Diabetes 1998; 47: 1544-1548
100. Coerver KA, Gray SM, Barnes JE, Armstrong DL, McCabe ER. Developmental expression of hexokinase 1 and 3 in rats. Histochem Cell Biol 1998; 109: 75-86.
101. Ferrer JC, Favre C, Gomis RR, Fernandez-Novell JM, Garcia-Rocha M, de la Iglesia N, et al. Control of glycogen deposition. FEBS Lett 2003; 546: 127-132
102. Wang H, Eckel RH. Lipoprotein lipase: from gene to obesity. Am J Physiol Endocrinol Metab 2009; 297: E271-88.
103. Kiens B, Kristiansen S, Jensen P, Richter EA, Turcotte LP. Membrane associated fatty acid binding protein (FABPpm) in human skeletal muscle is increased by endurance training. Biochem Biophys Res Commun 1997; 231: 463-465
104. Turcotte LP, Srivastava AK, Chiasson JL. Fasting increases plasma membrane fatty acid-binding protein (FABP(PM)) in red skeletal muscle. Mol Cell Biochem 1997; 166: 153-158
105. Schaffer JE, Lodish HF. Expression cloning and characterization of a novel adipocyte long chain fatty acid transport protein. Cell 1994; 79: 427-436
106. Kiens B, Lithell H, Mikines KJ, Richter EA. Effects of insulin and exercise on muscle lipoprotein lipase activity in man and its relation to insulin action. J Clin Invest 1989; 84: 1124-1129
107. Ha J, Lee JK, Kim KS, Witters LA, Kim KH. Cloning of human acetyl-CoA carboxylase-beta and its unique features. Proc Natl Acad Sci USA 1996; 93: 11466-11470
108. Langfort J, Ploug T, Ihlemann J, Saldo M, Holm C, Galbo H. Expression of hormone-sensitive lipase and its regulation by adrenaline in skeletal muscle. Biochem J 1999; 340 (Pt 2): 459-465
109. Bastie CC, Nahle Z, McLoughlin T, Esser K, Zhang W, Unterman T, et al. FoxO1 stimulates fatty acid uptake and oxidation in muscle cells through CD36-dependent and -independent mechanisms. J Biol Chem 2005; 280: 14222-14229
110. Singh BM, Palma MA, Nattrass M. Multiple aspects of insulin resistance. Comparison of glucose and intermediary metabolite response to incremental insulin infusion in IDDM subjects of short and long duration. Diabetes 1987; 36: 740-748
111. Bagdade JD, Porte D, Jr., Bierman EL. Acute insulin withdrawal and the regulation of plasma triglyceride removal in diabetic subjects. Diabetes 1968; 17: 127-132
112. Taskinen MR, Nikkila EA. Lipoprotein lipase activity of adipose tissue and skeletal muscle in insulin-deficient human diabetes. Relation to high-density and very-low-density lipoproteins and response to treatment. Diabetologia 1979; 17: 351-356
113. Yechoor VK, Patti ME, Saccone R, Kahn CR. Coordinated patterns of gene expression for substrate and energy metabolism in skeletal muscle of diabetic mice. Proc Natl Acad Sci USA 2002; 99: 10587-10592
114. Laville M, Auboeuf D, Khalfallah Y, Vega N, Riou JP, Vidal H. Acute regulation by insulin of phosphatidylinositol-3-kinase, Rad, Glut 4, and lipoprotein lipase mRNA levels in human muscle. J Clin Invest 1996; 98: 43-49
115. Pendergrass M, Koval J, Vogt C, Yki-Jarvinen H, Iozzo P, Pipek R, et al. Insulin-induced hexokinase II expression is reduced in obesity and NIDDM. Diabetes 1998; 47: 387-394
116. Rome S, Clement K, Rabasa-Lhoret R, Loizon E, Poitou C, Barsh GS, et al. Microarray profiling of human skeletal muscle reveals that insulin regulates approximately 800 genes during a hyperinsulinemic clamp. J Biol Chem 2003; 278: 18063-18068
117. Dyck DJ, Steinberg G, Bonen A. Insulin increases FA uptake and esterification but reduces lipid utilization in isolated contracting muscle. Am J Physiol Endocrinol Metab 2001; 281: E600-7.
118. Yechoor VK, Patti ME, Ueki K, Laustsen PG, Saccone R, Rauniyar R, et al. Distinct pathways of insulin-regulated versus diabetes-regulated gene expression: an in vivo analysis in MIRKO mice. Proc Natl Acad Sci USA 2004; 101: 16525-16530
119. Luiken JJ, Arumugam Y, Bell RC, Calles-Escandon J, Tandon NN, Glatz JF, et al. Changes in fatty acid transport and transporters are related to the severity of insulin deficiency. Am J Physiol Endocrinol Metab 2002; 283: E612-21.
120. Sidossis LS, Wolfe RR. Glucose and insulin-induced inhibition of fatty acid oxidation: the glucose-fatty acid cycle reversed. Am J Physiol 1996; 270: E733-8.
121. Su CY, Payne M, Strauss AW, Dillmann WH. Selective reduction of creatine kinase subunit mRNAs in striated muscle of diabetic rats. Am J Physiol 1992; 263: E310-6.
122. Ventura-Clapier R, Kaasik A, Veksler V. Structural and functional adaptations of striated muscles to CK deficiency. Mol Cell Biochem 2004; 256-7: 29-41.
123. Wallimann T, Wyss M, Brdiczka D, Nicolay K, Eppenberger HM. Intracellular compartmentation, structure and function of creatine kinase isoenzymes in tissues with high and fluctuating energy demands: the 'phosphocreatine circuit' for cellular energy homeostasis. Biochem J 1992; 281 ( Pt 1): 21-40.
124. Gelfand RA, Barrett EJ. Effect of physiologic hyperinsulinemia on skeletal muscle protein synthesis and breakdown in man. J Clin Invest 1987; 80: 1-6.
125. Wang XD, Tang JG, Xie XL, Yang JC, Li S, Ji JG, et al. A comprehensive study of optimal conditions for naked plasmid DNA transfer into skeletal muscle by electroporation. J Gene Med 2005; 7: 1235-1245
126. Kon OL, Sivakumar S, Teoh KL, Lok SH, Long YC. Naked plasmid-mediated gene transfer to skeletal muscle ameliorates diabetes mellitus. J Gene Med 1999; 1: 186-194
127. Capaldo B, Home PD, Massi-Benedetti M, Worth R, Cook DB, Heaton A, et al. The response of blood intermediary metabolite levels to 24 hours treatment with a blood glucose-controlled insulin infusion system in type 1 diabetes. Diabetes Res 1984; 1: 187-193
128. Waldhausl W, Bratusch-Marrain P, Gasic S, Korn A, Nowotny P. Insulin production rate, hepatic insulin retention and splanchnic carbohydrate metabolism after oral glucose ingestion in hyperinsulinaemic Type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia 1982; 23: 6-15.
129. Zinman B, Marliss EB, Hanna AK, Minuk HL, Vranic M. Exercise in diabetic man: glucose turnover and free insulin responses after glycemic normalization with intravenous insulin. Can J Physiol Pharmacol 1982; 60: 1236-1240
130. Mandroukas K, Krotkiewski M, Holm G, Stromblad G, Grimby G, Lithell H, et al. Muscle adaptations and glucose control after physical training in insulin-dependent diabetes mellitus. Clin Physiol 1986; 6: 39-52.
131. Rivard A, Silver M, Chen D, Kearney M, Magner M, Annex B, et al. Rescue of diabetes-related impairment of angiogenesis by intramuscular gene therapy with adeno-VEGF. Am J Pathol 1999; 154: 355-363
132. Zacchigna S, Pattarini L, Zentilin L, Moimas S, Carrer A, Sinigaglia M, et al. Bone marrow cells recruited through the neuropilin-1 receptor promote arterial formation at the sites of adult neoangiogenesis in mice. J Clin Invest 2008; 118: 2062-2075
133. Tafuro S, Ayuso E, Zacchigna S, Zentilin L, Moimas S, Dore F, et al. Inducible adeno-associated virus vectors promote functional angiogenesis in adult organisms via regulated vascular endothelial growth factor expression. Cardiovasc Res 2009; 83: 663-671
134. Trujillo-Santos AJ. Diabetic muscle infarction: an underdiagnosed complication of long-standing diabetes. Diabetes Care 2003; 26: 211-215
135. Prud'homme GJ, Glinka Y, Khan AS, Draghia-Akli R. Electroporation- enhanced nonviral gene transfer for the prevention or treatment of immunological, endocrine and neoplastic diseases. Curr Gene Ther 2006; 6: 243-273
136. Prud'homme GJ, Lawson BR, Chang Y, Theofilopoulos AN. Immunotherapeutic gene transfer into muscle. Trends Immunol 2001; 22: 149-155
137. Yang Z, Chen M, Wu R, Fialkow LB, Bromberg JS, McDuffie M, et al. Suppression of autoimmune diabetes by viral IL-10 gene transfer. J Immunol 2002; 168: 6479-6485
138. Edwards CM. The GLP-1 system as a therapeutic target. Ann Med 2005; 37: 314-322
139. Hansotia T, Drucker DJ. GIP and GLP-1 as incretin hormones: lessons from single and double incretin receptor knockout mice. Regul Pept 2005; 128: 125-134
140. Casellas A, Salavert A, Agudo J, Ayuso E, Jimenez V, Moya M, et al. Expression of IGF-I in pancreatic islets prevents lymphocytic infiltration and protects mice from type 1 diabetes. Diabetes 2006; 55: 3246-3255
141. Mingozzi F, Meulenberg JJ, Hui DJ, Basner-Tschakarjan E, Hasbrouck NC, Edmonson SA, et al. AAV-1-mediated gene transfer to skeletal muscle in humans results in dose-dependent activation of capsid-specific T cells. Blood 2009; 114: 2077-2086
142. Rip J, Sierts JA, Vaessen SF, Kastelein JJ, Twisk J, Kuivenhoven JA. Adeno-associated virus LPL(S447X) gene therapy in LDL receptor knockout mice. Atherosclerosis 2007; 194: 55-61.
143. Ropper AH, Gorson KC, Gooch CL, Weinberg DH, Pieczek A, Ware JH, et al. Vascular endothelial growth factor gene transfer for diabetic polyneuropathy: a randomized, double-blinded trial. Ann Neurol 2009; 65: 386-393
144. Sawyer GJ, Rela M, Davenport M, Whitehorne M, Zhang X, Fabre JW. Hydrodynamic gene delivery to the liver: theoretical and practical issues for clinical application. Curr Gene Ther 2009; 9: 128-135
145. Kozlowski M, Olson DE, Rubin J, Lyszkowicz D, Campbell A, Thule PM. Adeno-associated viral delivery of a metabolically regulated insulin transgene to hepatocytes. Mol Cell Endocrinol 2007; 273: 6-15.
146. Sugiyama A, Hattori S, Tanaka S, Isoda F, Kleopoulos S, Rosenfeld M, et al. Defective adenoassociated viral-mediated transfection of insulin gene by direct injection into liver parenchyma decreases blood glucose of diabetic mice. Horm Metab Res 1997; 29: 599-603.
147. Short DK, Okada S, Yamauchi K, Pessin JE. Adenovirus-mediated transfer of a modified human proinsulin gene reverses hyperglycemia in diabetic mice. Am J Physiol 1998; 275: E748-56.
148. Hsu PY, Yang YW. Effect of polyethylenimine on recombinant adeno-associated virus mediated insulin gene therapy. J Gene Med 2005; 7: 1311-1321
149. Alter J, Lou F, Rabinowitz A, Yin H, Rosenfeld J, Wilton SD, et al. Systemic delivery of morpholino oligonucleotide restores dystrophin expression bodywide and improves dystrophic pathology. Nat Med 2006; 12: 175-177
150. Toromanoff A, Cherel Y, Guilbaud M, Penaud-Budloo M, Snyder RO, Haskins ME, et al. Safety and efficacy of regional intravenous (r.i.) versus intramuscular (i.m.) delivery of rAAV1 and rAAV8 to nonhuman primate skeletal muscle. Mol Ther 2008; 16: 1291-1299
151. Hagstrom JE, Hegge J, Zhang G, Noble M, Budker V, Lewis DL, et al. A facile nonviral method for delivering genes and siRNAs to skeletal muscle of mammalian limbs. Mol Ther 2004; 10: 386-398
152. Gregorevic P, Blankinship MJ, Allen JM, Crawford RW, Meuse L, Miller DG, et al. Systemic delivery of genes to striated muscles using adeno-associated viral vectors. Nat Med 2004; 10: 828-834
153. Wells DJ. Viral and non-viral methods for gene transfer into skeletal muscle. Curr Opin Drug Discov Develop 2006; 9: 163-168
154. Alexander IE, Cunningham SC, Logan GJ, Christodoulou J. Potential of AAV vectors in the treatment of metabolic disease. Gene Ther 2008; 15: 831-839
155. el Oakley RM, Brand NJ, Burton PB, McMullen MC, Adams GB, Poznansky MC, et al. Efficiency of a high-titer retroviral vector for gene transfer into skeletal myoblasts. J Thorac Cardiovasc Surg 1998; 115: 1-8.
156. Kafri T, Blomer U, Peterson DA, Gage FH, Verma IM. Sustained expression of genes delivered directly into liver and muscle by lentiviral vectors. Nat Genet 1997; 17: 314-317
157. O'Rourke JP, Hiraragi H, Urban K, Patel M, Olsen JC, Bunnell BA. Analysis of gene transfer and expression in skeletal muscle using enhanced EIAV lentivirus vectors. Mol Ther 2003; 7: 632-639
158. Yoshimitsu M, Higuchi K, Dawood F, Rasaiah VI, Ayach B, Chen M, et al. Correction of cardiac abnormalities in fabry mice by direct intraventricular injection of a recombinant lentiviral vector that engineers expression of alpha-galactosidase A. Circ J 2006; 70: 1503-1508
159. Peng KW, Pham L, Ye H, Zufferey R, Trono D, Cosset FL, et al. Organ distribution of gene expression after intravenous infusion of targeted and untargeted lentiviral vectors. Gene Ther 2001; 8: 1456-1463
160. Bergelson JM, Cunningham JA, Droguett G, Kurt-Jones EA, Krithivas A, Hong JS, et al. Isolation of a common receptor for Coxsackie B viruses and adenoviruses 2 and 5. Science 1997; 275: 1320-1323
161. Tomko RP, Xu R, Philipson L. HCAR and MCAR: the human and mouse cellular receptors for subgroup C adenoviruses and group B coxsackieviruses. Proc Natl Acad Sci USA 1997; 94: 3352-3356
162. Acsadi G, Jani A, Massie B, Simoneau M, Holland P, Blaschuk K, et al. A differential efficiency of adenovirus-mediated in vivo gene transfer into skeletal muscle cells of different maturity. Hum Mol Genet 1994; 3: 579-584
163. Feero WG, Rosenblatt JD, Huard J, Watkins SC, Epperly M, Clemens PR, et al. Viral gene delivery to skeletal muscle: insights on maturation-dependent loss of fiber infectivity for adenovirus and herpes simplex type 1 viral vectors. Hum Gene Ther 1997; 8: 371-380
164. Kass-Eisler A, Falck-Pedersen E, Elfenbein DH, Alvira M, Buttrick PM, Leinwand LA. The impact of developmental stage, route of administration and the immune system on adenovirus-mediated gene transfer. Gene Ther 1994; 1: 395-402.
165. Nalbantoglu J, Pari G, Karpati G, Holland PC. Expression of the primary coxsackie and adenovirus receptor is downregulated during skeletal muscle maturation and limits the efficacy of adenovirus-mediated gene delivery to muscle cells. Hum Gene Ther 1999; 10: 1009-1019
166. Alemany R, Curiel DT. CAR-binding ablation does not change biodistribution and toxicity of adenoviral vectors. Gene Ther 2001; 8: 1347-1353
167. O'Hara AJ, Howell JM, Taplin RH, Fletcher S, Lloyd F, Kakulas B, et al. The spread of transgene expression at the site of gene construct injection. Muscle Nerve 2001; 24: 488-495
168. Yang Y, Nunes FA, Berencsi K, Furth EE, Gonczol E, Wilson JM. Cellular immunity to viral antigens limits E1-deleted adenoviruses for gene therapy. Proc Natl Acad Sci USA 1994; 91: 4407-4411
169. Parks RJ, Chen L, Anton M, Sankar U, Rudnicki MA, Graham FL. A helper-dependent adenovirus vector system: removal of helper virus by Cre-mediated excision of the viral packaging signal. Proc Natl Acad Sci USA 1996; 93: 13565-13570
170. Morral N, O'Neal W, Rice K, Leland M, Kaplan J, Piedra PA, et al. Administration of helper-dependent adenoviral vectors and sequential delivery of different vector serotype for long-term liver-directed gene transfer in baboons. Proc Natl Acad Sci USA 1999; 96: 12816-12821
171. Bangari DS, Mittal SK. Development of nonhuman adenoviruses as vaccine vectors. Vaccine 2006; 24: 849-862
172. Tatsis N, Ertl HC. Adenoviruses as vaccine vectors. Mol Ther 2004; 10: 616-629
173. Yla-Herttuala S. An update on angiogenic gene therapy: vascular endothelial growth factor and other directions. Curr Opin Mol Ther 2006; 8: 295-300.
174. Niemeyer GP, Herzog RW, Mount J, Arruda VR, Tillson DM, Hathcock J, et al. Long-term correction of inhibitor-prone hemophilia B dogs treated with liver-directed AAV2-mediated factor IX gene therapy. Blood 2009; 113: 797-806.
175. Herzog RW, Yang EY, Couto LB, Hagstrom JN, Elwell D, Fields PA, et al. Long-term correction of canine hemophilia B by gene transfer of blood coagulation factor IX mediated by adeno-associated viral vector. Nat Med 1999; 5: 56-63.
176. Herzog RW, Hagstrom JN, Kung SH, Tai SJ, Wilson JM, Fisher KJ, et al. Stable gene transfer and expression of human blood coagulation factor IX after intramuscular injection of recombinant adeno-associated virus. Proc Natl Acad Sci USA 1997; 94: 5804-5809
177. Gao GP, Alvira MR, Wang L, Calcedo R, Johnston J, Wilson JM. Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy. Proc Natl Acad Sci USA 2002; 99: 11854-11859
178. Wang Z, Kuhr CS, Allen JM, Blankinship M, Gregorevic P, Chamberlain JS, et al. Sustained AAV-mediated dystrophin expression in a canine model of Duchenne muscular dystrophy with a brief course of immunosuppression. Mol Ther 2007; 15: 1160-1166
179. Bish LT, Morine K, Sleeper MM, Sanmiguel J, Wu D, Gao G, et al. Adeno-associated virus (AAV) serotype 9 provides global cardiac gene transfer superior to AAV1, AAV6, AAV7, and AAV8 in the mouse and rat. Hum Gene Ther 2008; 19: 1359-1368
180. Wang Z, Zhu T, Qiao C, Zhou L, Wang B, Zhang J, et al. Adeno-associated virus serotype 8 efficiently delivers genes to muscle and heart. Nat Biotechnol 2005; 23: 321-328
181. Yu CY, Yuan Z, Cao Z, Wang B, Qiao C, Li J, et al. A muscle-targeting
182. Braun S. Muscular gene transfer using nonviral vectors. Curr Gene Ther 2008; 8: 391-405.
183. Aigner A. Nonviral in vivo delivery of therapeutic small interfering RNAs. Curr Opin Mol Ther 2007; 9: 345-352
184. Li SD, Huang L. Gene therapy progress and prospects: non-viral gene therapy by systemic delivery. Gene Ther 2006; 13: 1313-1319
185. Frederickson RM, Carter BJ, Pilaro AM. Nonclinical toxicology in support of licensure of gene therapies. Arlington, VA, USA, March 13-14, 2003. Mol Ther 2003; 8: 8-10.
186. Ratanamart J, Huggins CG, Kirby JA, Shaw JA. In vitro and in vivo evaluation of intrinsic immunogenicity of reporter and insulin gene therapy plasmids. J Gene Med 2007; 9: 703-714
187. Krieg AM. Direct immunologic activities of CpG DNA and implications for gene therapy. J Gene Med 1999; 1: 56-63.
188. Andre F, Mir LM. DNA electrotransfer: its principles and an updated review of its therapeutic applications. Gene Ther 2004; 11 (Suppl 1): S33-42.
189. Heller LC, Heller R. In vivo electroporation for gene therapy. Hum Gene Ther 2006; 17: 890-897
190. Satkauskas S, Andre F, Bureau MF, Scherman D, Miklavcic D, Mir LM. Electrophoretic component of electric pulses determines the efficacy of in vivo DNA electrotransfer. Hum Gene Ther 2005; 16: 1194-1201
191. McMahon JM, Signori E, Wells KE, Fazio VM, Wells DJ. Optimisation of electrotransfer of plasmid into skeletal muscle by pretreatment with hyaluronidase - increased expression with reduced muscle damage. Gene Ther 2001; 8: 1264-1270
192. Friso A, Tomanin R, Zanetti A, Mennuni C, Calvaruso F, La Monica N, et al. Gene therapy of Hunter syndrome: evaluation of the efficiency of muscle electro gene transfer for the production and release of recombinant iduronate-2-sulfatase (IDS). Biochim Biophys Acta 2008; 1782: 574-580
193. Mir LM. Nucleic acids electrotransfer-based gene therapy (Electrogenetherapy): Past, Current, and Future. Mol Biotechnol 2009; 43(2): 107-176
194. Poitout V, Stein R, Rhodes CJ. In: DeFronzo R, Ferrannini E, Keen H, Zimmet P, Eds. International textbook of diabetes, third edition. Chichester, John Wiley and Sons, Ltd. 2004; vol.1, pp. 97-123.
195. Johansson BL, Kernell A, Sjoberg S, Wahren J. Influence of combined C-peptide and insulin administration on renal function and metabolic control in diabetes type 1. J Clin Endocrinol Metab 1993; 77: 976-981
196. Ido Y, Vindigni A, Chang K, Stramm L, Chance R, Heath WF, et al. Prevention of vascular and neural dysfunction in diabetic rats by C-peptide. Science 1997; 277: 563-566
197. Sjoquist M, Huang W, Johansson BL. Effects of C-peptide on renal function at the early stage of experimental diabetes. Kidney Int 1998; 54: 758-764
198. Zierath JR, Handberg A, Tally M, Wallberg-Henriksson H. C-peptide stimulates glucose transport in isolated human skeletal muscle independent of insulin receptor and tyrosine kinase activation. Diabetologia 1996; 39: 306-313
199. Abai AM, Hobart PM, Barnhart KM. Insulin delivery with plasmid DNA. Hum Gene Ther 1999; 10: 2637-2649
200. Croze F, Prud'homme GJ. Gene therapy of streptozotocin-induced diabetes by intramuscular delivery of modified preproinsulin genes. J Gene Med 2003; 5: 425-437
201. Groskreutz DJ, Sliwkowski MX, Gorman CM. Genetically engineered proinsulin constitutively processed and secreted as mature, active insulin. J Biol Chem 1994; 269: 6241-6245
202. Gros L, Montoliu L, Riu E, Lebrigand L, Bosch F. Regulated production of mature insulin by non-beta-cells. Hum Gene Ther 1997; 8: 2249-2259
203. Galloway JA, Hooper SA, Spradlin CT, Howey DC, Frank BH, Bowsher RR, et al. Biosynthetic human proinsulin. Review of chemistry, in vitro and in vivo receptor binding, animal and human pharmacology studies, and clinical trial experience. Diabetes Care 1992; 15: 666-692
204. Richard M, Arfi A, Seguin J, Gandolphe C, Scherman D. Widespread biochemical correction of murine mucopolysaccharidosis type VII pathology by liver hydrodynamic plasmid delivery. Gene Ther 2009; 16: 746-756
205. Lee HC, Kim SJ, Kim KS, Shin HC, Yoon JW. Remission in models of type 1 diabetes by gene therapy using a single-chain insulin analogue. Nature 2000; 408: 483-488
206. Berger M. Safety of insulin glargine. Lancet 2000; 356: 2013-2014
207. Hansen BF, Danielsen GM, Drejer K, Sorensen AR, Wiberg FC, Klein HH, et al. Sustained signalling from the insulin receptor after stimulation with insulin analogues exhibiting increased mitogenic potency. Biochem J 1996; 315 (Pt 1): 271-279
208. Kurtzhals P, Schaffer L, Sorensen A, Kristensen C, Jonassen I, Schmid C, et al. Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use. Diabetes 2000; 49: 999-1005.
209. Smith U, Gale EA. Does diabetes therapy influence the risk of cancer? Diabetologia 2009; 52: 1699-1708
210. Herzog RW. Gene Therapy Immunology. Wiley-Blackwell: New Jersey 2009.
211. Mingozzi F, High KA. Immune responses to AAV in clinical trials. Curr Gene Ther 2007; 7: 316-324
212. Brown BD, Venneri MA, Zingale A, Sergi Sergi L, Naldini L. Endogenous microRNA regulation suppresses transgene expression in hematopoietic lineages and enables stable gene transfer. Nat Med 2006; 12: 585-591
213. Brown BD, Gentner B, Cantore A, Colleoni S, Amendola M, Zingale A, et al. Endogenous microRNA can be broadly exploited to regulate transgene expression according to tissue, lineage and differentiation state. Nat Biotechnol 2007; 25: 1457-1467
214. Brown BD, Cantore A, Annoni A, Sergi LS, Lombardo A, Della Valle P, et al. A microRNA-regulated lentiviral vector mediates stable correction of hemophilia B mice. Blood 2007; 110: 4144-4152
215. Blain M, Zeng Y, Bendjelloul M, Hallauer PL, Kumar A, Hastings KE, et al. Strong muscle specific regulatory cassettes based on multiple copies of the human slow troponin I gene upstream enhancer. Hum Gene Ther 2009; [Epub ahead of print].
216. Mori-Uchino M, Takeuchi T, Murakami I, Yano T, Yasugi T, Taketani Y, et al. Enhanced transgene expression in the mouse skeletal muscle infected by the adeno-associated viral vector with the human elongation factor 1α promoter and a human chromatin insulator. J Gene Med 2009; 11: 598-604.
217. Wang B, Li J, Fu FH, Chen C, Zhu X, Zhou L, et al. Construction and analysis of compact muscle-specific promoters for AAV vectors. Gene Ther 2008; 15: 1489-1499
218. Salva MZ, Himeda CL, Tai PW, Nishiuchi E, Gregorevic P, Allen JM, et al. Design of tissue-specific regulatory cassettes for highlevel rAAV-mediated expression in skeletal and cardiac muscle. Mol Ther 2007; 15: 320-329
219. Takeshita F, Takase K, Tozuka M, Saha S, Okuda K, Ishii N, et al. Muscle creatine kinase/SV40 hybrid promoter for muscle-targeted long-term transgene expression. Int J Mol Med 2007; 19: 309-315
220. Anderson CL, De Repentigny Y, Cifelli C, Marshall P, Renaud JM, Worton RG, et al. The mouse dystrophin muscle promoter/enhancer drives expression of mini-dystrophin in transgenic mdx mice and rescues the dystrophy in these mice. Mol Ther 2006; 14: 724-734
221. Stocksley MA, Chakkalakal JV, Bradford A, Miura P, De Repentigny Y, Kothary R, et al. A 1.3 kb promoter fragment confers spatial and temporal expression of utrophin A mRNA in mouse skeletal muscle fibers. Neuromuscul Disord 2005; 15: 437-449
222. De Repentigny Y, Marshall P, Worton RG, Kothary R. The mouse dystrophin muscle enhancer-1 imparts skeletal muscle, but not cardiac muscle, expression onto the dystrophin Purkinje promoter in transgenic mice. Hum Mol Genet 2004; 13: 2853-2862
223. Marshall P, Chartrand N, De Repentigny Y, Kothary R, Pelletier L, Mueller R, et al. Mouse dystrophin enhancer preferentially targets lacZ expression in skeletal and cardiac muscle. Dev Dyn 2002; 224: 30-38
224. Li X, Eastman EM, Schwartz RJ, Draghia-Akli R. Synthetic muscle promoters: activities exceeding naturally occurring regulatory sequences. Nat Biotechnol 1999; 17: 241-245
225. Martinenghi S, Cusella De Angelis G, Biressi S, Amadio S, Bifari F, Roncarolo MG, et al. Human insulin production and amelioration of diabetes in mice by electrotransfer-enhanced plasmid DNA gene transfer to the skeletal muscle. Gene Ther 2002; 9: 1429-1437
226. Andrali SS, Sampley ML, Vanderford NL, Ozcan S. Glucose regulation of insulin gene expression in pancreatic β-cells. Biochem J 2008; 415: 1-10.
227. Burkhardt BR, Loiler SA, Anderson JA, Kilberg MS, Crawford JM, Flotte TR, et al. Glucose-responsive expression of the human insulin promoter in HepG2 human hepatoma cells. Ann NY Acad Sci 2003; 1005: 237-241
228. Burkhardt BR, Parker MJ, Zhang YC, Song S, Wasserfall CH, Atkinson MA. Glucose transporter-2 (GLUT2) promoter mediated transgenic insulin production reduces hyperglycemia in diabetic mice. FEBS Lett 2005; 579: 5759-5764
229. Burkhardt BR, Yang MC, Robert CE, Greene SR, McFadden KK, Yang J, et al. Tissue-specific and glucose-responsive expression of the pancreatic derived factor (PANDER) promoter. Biochim Biophys Acta 2005; 1730: 215-225 (Pubitemid 41317466)
230. Won JC, Rhee BD, Ko KS. Glucose-responsive gene expression system for gene therapy. Adv Drug Deliv Rev 2009; 61: 633-640
231. Ma L, Sham YY, Walters KJ, Towle HC. A critical role for the loop region of the basic helix-loop-helix/leucine zipper protein Mlx in DNA binding and glucose-regulated transcription. Nucleic Acids Res 2007; 35: 35-44.
232. Meugnier E, Rome S, Vidal H. Regulation of gene expression by glucose. Curr Opin Clin Nutr Metab Care 2007; 10: 518-522
233. Scougall KT, Maltin CA, Shaw JA. Tetracycline-regulated secretion of human insulin in a transfected non-endocrine cell line. J Mol Endocrinol 2003; 30: 331-346
234. Scougall KT, Shaw JA. Tetracycline-regulated secretion of human insulin in transfected primary myoblasts. Biochem Biophys Res Commun 2003; 304: 167-175
235. Amendola M, Venneri MA, Biffi A, Vigna E, Naldini L. Coordinate dual-gene transgenesis by lentiviral vectors carrying synthetic bidirectional promoters. Nat Biotechnol 2005; 23: 108-116
236. Donello JE, Loeb JE, Hope TJ. Woodchuck hepatitis virus contains a tripartite posttranscriptional regulatory element. J Virol 1998; 72: 5085-5092
237. Tillmar L, Carlsson C, Welsh N. Control of insulin mRNA stability in rat pancreatic islets. Regulatory role of a 3′-untranslated region pyrimidine-rich sequence. J Biol Chem 2002; 277: 1099-1106
238. Welsh M, Nielsen DA, MacKrell AJ, Steiner DF. Control of insulin gene expression in pancreatic beta-cells and in an insulin-producing cell line, RIN-5F cells. II. Regulation of insulin mRNA stability. J Biol Chem 1985; 260: 13590-13594
239. Wicksteed B, Herbert TP, Alarcon C, Lingohr MK, Moss LG, Rhodes CJ. Cooperativity between the preproinsulin mRNA untranslated regions is necessary for glucose-stimulated translation. J Biol Chem 2001; 276: 22553-22558
240. Yang YW, Hsieh YC, Chao CK. Glucose-modulated transgene expression via recombinant adeno-associated virus. Pharm Res 2002; 19: 968-975
241. Jindal RM, Karanam M, Shah R. Prevention of diabetes in the NOD mouse by intra-muscular injection of recombinant adeno-associated virus containing the preproinsulin II gene. Int J Exp Diabetes Res 2001; 2: 129-138
242. Mas A, Montane J, Anguela XM, Munoz S, Douar AM, Riu E, et al. Reversal of type 1 diabetes by engineering a glucose sensor in skeletal muscle. Diabetes 2006; 55: 1546-1553
243. Peng L, Sidner RA, Bochan MR, Burton MM, Cooper ST, Jindal RM. Construction of recombinant adeno-associated virus vector containing the rat preproinsulin II gene. J Surg Res 1997; 69: 193-198
244. Oh TK, Li MZ, Kim ST. Gene therapy for diabetes mellitus in rats by intramuscular injection of lentivirus containing insulin gene. Diabetes Res Clin Pract 2006; 71: 233-240
245. Printz RL, Magnuson MA, Granner DK. Mammalian glucokinase. Annu Rev Nutr 1993; 13: 463-496
246. Otaegui PJ, Ontiveros M, Ferre T, Riu E, Jimenez R, Bosch F. Glucose-regulated glucose uptake by transplanted muscle cells expressing glucokinase counteracts diabetic hyperglycemia. Hum.Gene Ther. 2002; 13: 2125-2133
247. The DCCT Research Group. Diabetes Control and Complications Trial (DCCT): results of feasibility study. Diabetes Care 1987; 10: 1-19.
248. Cotugno G, Formisano P, Giacco F, Colella P, Beguinot F, Auricchio A. AP20187-mediated activation of a chimeric insulin receptor results in insulin-like actions in skeletal muscle and liver of diabetic mice. Hum Gene Ther 2007; 18: 106-117
249. Anderson HR, Stitt AW, Gardiner TA, Lloyd SJ, Archer DB. Induction of alloxan/streptozotocin diabetes in dogs: a revised experimental technique. Lab Anim 1993; 27: 281-285
250. Yin D, Tang JG. Gene therapy for streptozotocin-induced diabetic mice by electroporational transfer of naked human insulin precursor DNA into skeletal muscle in vivo. FEBS Lett 2001; 495: 16-20.
251. Leturque A, Loizeau M, Vaulont S, Salminen M, Girard J. Improvement of insulin action in diabetic transgenic mice selectively overexpressing GLUT4 in skeletal muscle. Diabetes 1996; 45: 23-27
252. Tsao TS, Burcelin R, Katz EB, Huang L, Charron MJ. Enhanced insulin action due to targeted GLUT4 overexpression exclusively in muscle. Diabetes 1996; 45: 28-36.
253. Abbatecola AM, Paolisso G. Is there a relationship between insulin resistance and frailty syndrome? Curr Pharm Des 2008; 14(4): 405-410
254. Heilbronn LK, Campbell LV. Adipose tissue macrophages, low grade inflammation and insulin resistance in human obesity. Curr Pharm Des 2008; 14(12): 1225-1230
255. Unoki H, Yamagishi S. Advanced glycation end products and insulin resistance. Curr Pharm Des 2008; 14(10): 987-989